S&P 500   4,567.00
DOW   34,483.72
QQQ   393.82
S&P 500   4,567.00
DOW   34,483.72
QQQ   393.82
S&P 500   4,567.00
DOW   34,483.72
QQQ   393.82
S&P 500   4,567.00
DOW   34,483.72
QQQ   393.82

Moderna Surges On Corona Virus Outbreak, Is Now The Time To Buy?

Wednesday, January 22, 2020 | Thomas Hughes
Moderna Inc, Is A Likely Player To Develop Vaccines For Wuhan Virus

Shares of Moderna Inc (MNRA) surged more than 6% in premarket trading and may be headed higher. The move is driven by a growing belief it will be a major player in the development of vaccines for China’s latest viral outbreak. The disease, a form of coronavirus, has already claimed the lives of nine people in China and more deaths are expected.

The first case of the new coronavirus has been found in the U.S. already. The victim, a male traveler from China, was found in Snohomish County, Washington and is now in isolation. Moderna is already working on vaccines for a number of commonly found illnesses so it makes sense they would tackle this one as well. Vaccines in the pipeline include those for CMV, RSV, hMPV, Zika, and H7N9 flu.

Labeled the Wuhan Coronavirus, symptoms for most are similar to a heavy cold or onset of pneumonia. So far, more than 400 cases have been diagnosed in China. The disease is highly contagious which makes it of particular concern this week. The Chinese Lunar New Year celebration will begin this weekend, 100’s of millions of people are expected to travel.

The CDC is already screening travelers at airports in California and New York. They will be expanding their screens to airports in Chicago, Atlanta and other airports with traffic coming from Wuhan, China. The World Health Organization will convene a panel soon to discuss making the Wuhan Virus a global health emergency. Along with the risk to world health, world leaders are thinking back to the SARS virus and its impact on the global economy.

Moderna Inc, At The Cutting Edge Of Today's Medicines

Moderna Inc is a clinical-stage biotechnology company. Clinical-stage means its vaccines and pipeline of drugs is ready to be or in the process of being tested on humans. It develops therapeutics and vaccines for infectious diseases, immuno-oncology, and rare diseases based on messenger RNA.

mRNA therapies are highly-advanced, cutting edge technologies that threaten to upturn the entire drug industry. They use the body as a drug-making machine, the mRNA is the means by which they do it. The mRNA delivers messages directly to cells telling them to produce complex proteins that cost millions to make in a factory.

The hurdle for Moderna, and others in the gene-therapy field, is that introducing the new mRNA into the body triggers an automatic response. The response includes shutting down protein production and effectively blocking any positive effects the mRNA may have. On top of that, there is concern that if the mRNA can be delivered and not trigger a negative response, it may not be able to make enough new proteins to matter.

The CEO Is Bullish, Clinical Trials Advance

Even so, there is a lot of work being done. Moderna has 11 drugs in clinical trials right now and 20 development projects in the pipeline. The company has collaborative deals with top-players like Astrazenaca (AZN), the Bill and Melinda Gates Foundation, Merck & Co (MRK), and the Biomedical Advanced Research and Development Authority.

Shares of Moderna got a boost a week or so ago after the company’s CEO appeared on Mad Money. Bottom line, CEO Stephane Bancel is bullish on Moderna’s prospects pointing out a-key drug is moving into the Phase III stage of trials. What this means is the company has proven its therapies can work, in this case for CMV (a common cold that can kill infants and elderly), now it has to prove they work better than today’s standards.

The Technical Outlook Is Bullish For This Risky Stock

The technical outlook is bullish. Today’s move began even before the outbreak of the Wuhan Virus and sets a new high. Sparked by the companies pipeline and outlook, this rally could have legs. The indicators support the breakout and suggest there is room for price action to run. The best targets for resistance are at the $24 and $29 levels, advances of 6% and 30% respectively.

Traders looking to get into this move are cautioned, Moderna is a high-risk growth stock so be extra cautious with position size. Also, price action will probably pull-back to support or consolidate in sideways action before moving higher so there is no need to rush in or chase prices. Patience will pay off.

Moderna Surges On Corona Virus Outbreak, Is Now The Time To Buy?
7 Pharmaceutical Stocks to Buy For a Healthy Portfolio in 2022

One year ago, investors expected 2021 to be a huge year for pharmaceutical stocks. The bullish perspective was that as vaccines rolled out and the economy reopened, investors would shift from biotech stocks to traditional pharmaceutical stocks.

But the Delta variant has kept Covid-19 top of mind for many investors. While it’s true that some pharmaceutical stocks were part of the vaccine race, other players in the space have not performed as well as was hoped. Case in point, as of October 6, 2021, the iShares U.S. Pharmaceuticals ETF (NYSEARCA:IHE) is up only 9.7% in the last 12 months. And if you bought shares of the fund at the beginning of the year, you have no growth to show for your patience.

There are reasons beyond Covid-19 to consider when assessing the disappointing performance of pharmaceutical stocks. One is the current political climate which is making no secret of its desire to reshape the healthcare industry. And it has the pricing practices of “big pharma” firmly in its crosshairs.

However, the pharmaceutical sector is still loaded with quality stocks for investors who are willing to accept the inherent risk. And that’s the focus of this special presentation. In the next few minutes, we’ll take a look at seven pharmaceutical stocks that are ready to make strong moves forward in 2022.

View the "7 Pharmaceutical Stocks to Buy For a Healthy Portfolio in 2022".


Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research.